1 to hit Australian shelves within days
The TGA has approved Lilly's oral GLP-1 medication, orforglipron, for the treatment of obesity and type 2 diabetes in Australia. The drug will be available for prescription in the coming days, offering a non-peptide alternative to existing injectable treatments.
Why it matters
This marks a significant shift in obesity and diabetes management by providing an oral medication option that may improve patient adherence and accessibility.
The TGA has approved Foundayo for obesity and type 2 diabetes, with the pill ready for prescription 'in the coming days' and dispensed from Lilly's own platform and pharmacists.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in